BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nemati S, Hassanzadeh R, Khajeh Jahromi S, Delkhosh Nasrollah Abadi A. Otomycosis in the north of Iran: common pathogens and resistance to antifungal agents. Eur Arch Otorhinolaryngol 2014;271:953-7. [PMID: 23595615 DOI: 10.1007/s00405-013-2486-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Téné N, Bonnafé E, Berger F, Rifflet A, Guilhaudis L, Ségalas-milazzo I, Pipy B, Coste A, Leprince J, Treilhou M. Biochemical and biophysical combined study of bicarinalin, an ant venom antimicrobial peptide. Peptides 2016;79:103-13. [DOI: 10.1016/j.peptides.2016.04.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
2 Kamali Sarwestani Z, Hashemi SJ, Rezaie S, Gerami Shoar M, Mahmoudi S, Elahi M, Bahardoost M, Tajdini A, Abutalebian S, Daie Ghazvini R. Species identification and in vitro antifungal susceptibility testing of Aspergillus section Nigri strains isolated from otomycosis patients. J Mycol Med 2018;28:279-84. [PMID: 29540288 DOI: 10.1016/j.mycmed.2018.02.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
3 Kiakojuri K, Mahdavi Omran S, Roodgari S, Taghizadeh Armaki M, Hedayati MT, Shokohi T, Haghani I, Javidnia J, Kermani F, Badali H, Abastabar M. Molecular Identification and Antifungal Susceptibility of Yeasts and Molds Isolated from Patients with Otomycosis. Mycopathologia 2021;186:245-57. [PMID: 33718990 DOI: 10.1007/s11046-021-00537-1] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Kiakojuri K, Armaki MT, Rajabnia R, Pournajaf A, Karami M, Khademian A, Omran SM. Outer Ear Infections in Iran: A Review. Open Access Maced J Med Sci 2019;7:1233-40. [PMID: 31049113 DOI: 10.3889/oamjms.2019.176] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
5 Salari S, Ayatollahi Mousavi SA, Hadizadeh S, Izadi A. Epidemiology of dermatomycoses in Kerman province, southeast of Iran: A 10-years retrospective study (2004-2014). Microb Pathog 2017;110:561-7. [PMID: 28757272 DOI: 10.1016/j.micpath.2017.07.043] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
6 Kiakojuri K, Rajabnia R, Jalili B, Khafri S, Omran SM. Otomycosis in Adolescent Patients Referred to the Therapeutic Centers in Babol City, Iran. Jundishapur J Microbiol 2015;8:e17138. [PMID: 26060563 DOI: 10.5812/jjm.8(5)2015.17138] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
7 Gharaghani M, Halvaeezadeh M, Ali Jalaee G, Taghipour S, Kiasat N, Zarei Mahmoudabadi A. Antifungal susceptibility profiles of otomycosis etiological agents in Ahvaz, Iran. Curr Med Mycol 2020;6:18-22. [PMID: 33628977 DOI: 10.18502/CMM.6.2.2696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Kiakojuri K, Rajabnia R, Mahdavi Omran S, Pournajaf A, Karami M, Taghizadeh Armaki M. Role of Clotrimazole in Prevention of Recurrent Otomycosis. Biomed Res Int 2019;2019:5269535. [PMID: 31950041 DOI: 10.1155/2019/5269535] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Zarei Mahmoudabadi A, Seifi Z, Gharaghani M. Lamisil, a potent alternative antifungal drug for otomycosis. Curr Med Mycol 2015;1:18-21. [PMID: 28680976 DOI: 10.18869/acadpub.cmm.1.1.18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
10 Gharaghani M, Seifi Z, Zarei Mahmoudabadi A. Otomycosis in iran: a review. Mycopathologia 2015;179:415-24. [PMID: 25633436 DOI: 10.1007/s11046-015-9864-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
11 Mahdavi Omran S, Yousefzade Z, Khafri S, Taghizadeh-Armaki M, Kiakojuri K. Effect of combination therapy with ceftizoxime and clotrimazole in the treatment of otomycosis. Curr Med Mycol 2018;4:18-23. [PMID: 30186989 DOI: 10.18502/cmm.4.1.30] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Aboutalebian S, Mahmoudi S, Mirhendi H, Okhovat A, Abtahi H, Chabavizadeh J. Molecular epidemiology of otomycosis in Isfahan revealed a large diversity in causative agents. J Med Microbiol 2019;68:918-23. [PMID: 31063125 DOI: 10.1099/jmm.0.000985] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
13 Aboutalebian S, Mahmoudi S, Okhovat A, Khodavaisy S, Mirhendi H. Otomycosis Due to the Rare Fungi Talaromyces purpurogenus, Naganishia albida and Filobasidium magnum. Mycopathologia 2020;185:569-75. [PMID: 32232764 DOI: 10.1007/s11046-020-00439-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
14 Wu S, Cheng Y, Lin S, Liu H. A Comparison of Antifungal Drugs and Traditional Antiseptic Medication for Otomycosis Treatment: A Systematic Review and Meta-Analysis. Front Surg 2021;8:739360. [PMID: 35004834 DOI: 10.3389/fsurg.2021.739360] [Reference Citation Analysis]
15 Abo-Zed A, Phan T. Tympanic membrane perforation secondary to Aspergillus niger otomycosis. IDCases 2020;22:e00944. [PMID: 32963962 DOI: 10.1016/j.idcr.2020.e00944] [Reference Citation Analysis]
16 Cheraghsahar S, Kazemi S, Birjandi M, Yarahmadi M, Mahmoudi S, Mohammadi R, Sepahvand A. Otomycosis in Western Iran: Clinical and Mycological Aspects. Arch Clin Infect Dis 2017;In Press. [DOI: 10.5812/archcid.57287] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]